XML 43 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Disclosures (Tables)
6 Months Ended
May 31, 2020
Fair Value Disclosures [Abstract]  
Financial Assets and Liabilities Accounted for at Fair Value on Recurring Basis
The following is a summary of our financial assets and liabilities that are accounted for at fair value on a recurring basis, excluding Investments at fair value based on net asset value (“NAV”) of $905.5 million and $570.3 million at May 31, 2020 and November 30, 2019, respectively, by level within the fair value hierarchy (in thousands):
 
May 31, 2020
 
Level 1
 
Level 2
 
Level 3
 
Counterparty and
Cash Collateral
Netting (1)
 
Total
Assets:
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
2,461,993

 
$
61,387

 
$
76,100

 
$

 
$
2,599,480

Corporate debt securities

 
2,979,793

 
25,178

 

 
3,004,971

Collateralized debt obligations and collateralized loan obligations

 
68,748

 
23,139

 

 
91,887

U.S. government and federal agency securities
1,808,192

 
72,411

 

 

 
1,880,603

Municipal securities

 
462,420

 

 

 
462,420

Sovereign obligations
2,088,074

 
1,307,336

 

 

 
3,395,410

Residential mortgage-backed securities

 
1,688,379

 
22,339

 

 
1,710,718

Commercial mortgage-backed securities

 
355,161

 
4,461

 

 
359,622

Other asset-backed securities

 
292,158

 
86,062

 

 
378,220

Loans and other receivables

 
2,546,340

 
68,429

 

 
2,614,769

Derivatives
515

 
2,070,181

 
43,124

 
(1,528,340
)
 
585,480

Investments at fair value

 
71,860

 
63,959

 

 
135,819

Total financial instruments owned, excluding Investments at fair value based on NAV
$
6,358,774

 
$
11,976,174

 
$
412,791

 
$
(1,528,340
)
 
$
17,219,399

Securities received as collateral
$
9,909

 
$

 
$

 
$

 
$
9,909

 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
1,772,771

 
$
1,283

 
$
4,190

 
$

 
$
1,778,244

Corporate debt securities

 
1,491,089

 
163

 

 
1,491,252

U.S. government and federal agency securities
2,140,501

 

 

 

 
2,140,501

Sovereign obligations
1,132,662

 
878,059

 

 

 
2,010,721

Commercial mortgage-backed securities

 

 
140

 

 
140

Loans

 
1,796,591

 
10,674

 

 
1,807,265

Derivatives
277

 
2,012,054

 
88,255

 
(1,682,883
)
 
417,703

Total financial instruments sold, not yet purchased
$
5,046,211

 
$
6,179,076

 
$
103,422

 
$
(1,682,883
)
 
$
9,645,826

Short-term borrowings
$

 
$
15,671

 
$

 
$

 
$
15,671

Obligation to return securities received as collateral
$
9,909

 
$

 
$

 
$

 
$
9,909

Long-term debt
$

 
$
748,446

 
$
497,040

 
$

 
$
1,245,486

(1)
Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty.
 
November 30, 2019
 
Level 1
 
Level 2
 
Level 3
 
Counterparty and
Cash Collateral
Netting (1)
 
Total
Assets:
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
2,325,116

 
$
218,403

 
$
58,301

 
$

 
$
2,601,820

Corporate debt securities

 
2,472,213

 
7,490

 

 
2,479,703

Collateralized debt obligations and collateralized loan obligations

 
124,225

 
20,081

 

 
144,306

U.S. government and federal agency securities
2,101,624

 
158,618

 

 

 
2,260,242

Municipal securities

 
742,326

 

 

 
742,326

Sovereign obligations
1,330,026

 
1,405,827

 

 

 
2,735,853

Residential mortgage-backed securities

 
1,069,066

 
17,740

 

 
1,086,806

Commercial mortgage-backed securities

 
424,060

 
6,110

 

 
430,170

Other asset-backed securities

 
303,847

 
42,563

 

 
346,410

Loans and other receivables

 
2,395,211

 
64,240

 

 
2,459,451

Derivatives
2,809

 
1,812,659

 
14,889

 
(1,432,806
)
 
397,551

Investments at fair value

 
32,688

 
75,738

 

 
108,426

Total financial instruments owned, excluding Investments at fair value based on NAV
$
5,759,575

 
$
11,159,143

 
$
307,152

 
$
(1,432,806
)
 
$
15,793,064

Securities purchased under agreements to resell
$

 
$

 
$
25,000

 
$

 
$
25,000

Securities received as collateral
$
9,500

 
$

 
$

 
$

 
$
9,500

 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
2,755,601

 
$
7,438

 
$
4,487

 
$

 
$
2,767,526

Corporate debt securities

 
1,471,142

 
340

 

 
1,471,482

U.S. government and federal agency securities
1,851,981

 

 

 

 
1,851,981

Sovereign obligations
1,363,475

 
941,065

 

 

 
2,304,540

Commercial mortgage-backed securities

 

 
35

 

 
35

Loans

 
1,600,228

 
9,463

 

 
1,609,691

Derivatives
871

 
2,066,064

 
92,057

 
(1,631,787
)
 
527,205

Total financial instruments sold, not yet purchased
$
5,971,928

 
$
6,085,937

 
$
106,382

 
$
(1,631,787
)
 
$
10,532,460

Short-term borrowings
$

 
$
20,981

 
$

 
$

 
$
20,981

Obligation to return securities received as collateral
$
9,500

 
$

 
$

 
$

 
$
9,500

Long-term debt
$

 
$
735,216

 
$
480,069

 
$

 
$
1,215,285

(1)
Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty.
Investments Measured at Fair Value Based on Net Asset Value Per Share
The following tables present information about our investments in entities that have the characteristics of an investment company (in thousands):
 
May 31, 2020
 
Fair Value (1)
 
Unfunded
Commitments
Equity Long/Short Hedge Funds (2)
$
302,790

 
$

Equity Funds (3)
21,182

 
11,823

Commodity Funds (4)
13,593

 

Multi-asset Funds (5)
543,191

 

Other Funds (6)
24,728

 

Total
$
905,484

 
$
11,823

 
November 30, 2019
 
Fair Value (1)
 
Unfunded
Commitments
Equity Long/Short Hedge Funds (2)
$
291,593

 
$

Equity Funds (3)
27,952

 
12,108

Commodity Funds (4)
16,025

 

Multi-asset Funds (5)
234,583

 

Other Funds (6)
157

 

Total
$
570,310

 
$
12,108

(1)
Where fair value is calculated based on NAV, fair value has been derived from each of the funds’ capital statements.
(2)
This category includes investments in hedge funds that invest, long and short, primarily in both public and private equity securities in domestic and international markets. At both May 31, 2020 and November 30, 2019, approximately 6% of the fair value of investments in this category are redeemable quarterly with 60 days prior written notice.
(3)
At May 31, 2020 and November 30, 2019, the investments in this category include investments in equity funds that invest in the equity of various U.S. and foreign private companies in the energy, technology, internet service and telecommunication service industries. These investments cannot be redeemed; instead, distributions are received through the liquidation of the underlying assets of the funds which are primarily expected to be liquidated in approximately one to nine years.
(4)
This category includes investments in a hedge fund that invests, long and short, primarily in commodities. Investments in this category are redeemable quarterly with 60 days prior written notice.
(5)
This category includes investments in hedge funds that invest, long and short, primarily in multi-asset securities in domestic and international markets in both the public and private sectors. At May 31, 2020 and November 30, 2019, investments representing approximately 58% and 5%, respectively, of the fair value of investments in this category are redeemable monthly with 30 or 60 days prior written notice.
(6)
This category includes investments in a fund that trades and invests in structured finance securities. At May 31, 2020 and November 30, 2019, investments in this category representing approximately 99% and 0%, respectively, are redeemable quarterly with 12 months prior written notice.
Summary of Changes in Fair Value of Financial Assets and Liabilities Classified as Level 3
The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the three months ended May 31, 2020 (in thousands):

 
Three Months Ended May 31, 2020
 
 
 
Balance at February 29, 2020
 
Total gains/losses (realized and unrealized) (1)
 
Purchases
 
Sales
 
Settlements
 
Issuances
 
Net transfers into/
(out of) Level 3
 
Balance at May 31, 2020
 
For instruments still held at
May 31, 2020 changes in unrealized
 gains/(losses) included in:
 
Earnings (1)
 
Other comprehensive income (1)
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
103,643

 
$
(5,319
)
 
$
36

 
$
(68
)
 
$

 
$

 
$
(22,192
)
 
$
76,100

 
$
(5,220
)
 
$

Corporate debt securities
25,090

 
(1,480
)
 
328

 
(365
)
 
(1
)
 

 
1,606

 
25,178

 
(1,464
)
 

CDOs and CLOs
20,952

 
(12,879
)
 

 
(8,471
)
 
(1,673
)
 

 
25,210

 
23,139

 
(16,031
)
 

RMBS
16,970

 
(1,773
)
 
1,380

 

 
(7
)
 

 
5,769

 
22,339

 
(1,733
)
 

CMBS
4,264

 
53

 

 

 

 

 
144

 
4,461

 
53

 

Other ABS
41,903

 
(2,380
)
 
11,038

 

 
(8,490
)
 

 
43,991

 
86,062

 
(5,087
)
 

Loans and other receivables
54,321

 
(4,891
)
 
45,984

 
(46,939
)
 
(128
)
 

 
20,082

 
68,429

 
(4,847
)
 

Investments at fair value
55,270

 
(10,805
)
 
400

 
(91
)
 

 

 
19,185

 
63,959

 
(10,805
)
 

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
4,275

 
$
(60
)
 
$

 
$

 
$

 
$

 
$
(25
)
 
$
4,190

 
$
60

 
$

Corporate debt securities
767

 
(23
)
 
(20
)
 

 

 

 
(561
)
 
163

 

 

CMBS
35

 

 

 
105

 

 

 

 
140

 

 

Loans
7,859

 
1,015

 
(2,785
)
 
3,290

 

 

 
1,295

 
10,674

 
(1,015
)
 

Net derivatives (2)
110,843

 
(32,744
)
 
(10,810
)
 
33,196

 
(603
)
 

 
(54,751
)
 
45,131

 
34,259

 

Long-term debt
543,463

 
(92,480
)
 

 

 

 
66,916

 
(20,859
)
 
497,040

 
664

 
91,816

(1)
Realized and unrealized gains/losses are primarily reported in Principal transactions revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes are included in our Consolidated Statement of Comprehensive Income, net of tax.
(2)
Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.
The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the three months ended May 31, 2019 (in thousands):
 
Three Months Ended May 31, 2019
 
 
 
Balance at February 28, 2019
 
Total gains/losses (realized and unrealized) (1)
 
Purchases
 
Sales
 
Settlements
 
Issuances
 
Net transfers into/
(out of) Level 3
 
Balance at May 31, 2019
 
For instruments still held at
May 31, 2019, changes in unrealized gains/(losses) included in:
 
Earnings (1)
 
Other comprehensive income (1)
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
54,766

 
$
2,353

 
$
221

 
$
(179
)
 
$
(551
)
 
$

 
$
2,697

 
$
59,307

 
$
2,454

 
$

Corporate debt securities
10,930

 
(587
)
 
180

 

 
(325
)
 

 
(2,769
)
 
7,429

 
(588
)
 

CDOs and CLOs
32,566

 
(1,793
)
 

 

 

 

 
(14,578
)
 
16,195

 
(1,795
)
 

RMBS
20,963

 
(802
)
 

 

 
(18
)
 

 
(2,877
)
 
17,266

 
(759
)
 

CMBS
12,820

 
(357
)
 

 
(331
)
 
(3,238
)
 

 
3,636

 
12,530

 
(1,292
)
 

Other ABS
35,886

 
3,070

 
16,531

 
(8,868
)
 
(8,549
)
 

 
5,115

 
43,185

 
3,563

 

Loans and other receivables
78,051

 
(2,753
)
 
38,780

 
(13,898
)
 
(2,438
)
 

 
742

 
98,484

 
(1,277
)
 

Investments at fair value
140,812

 
2,841

 

 

 

 

 
(39,820
)
 
103,833

 
2,841

 

Securities purchased under agreements to resell

 

 

 

 

 
25,000

 

 
25,000

 

 

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
78

 
$
(74
)
 
$
(1,520
)
 
$
1,737

 
$

 
$

 
$

 
$
221

 
$

 
$

Corporate debt securities
730

 
(148
)
 
(7
)
 
1

 
22

 

 
71

 
669

 
90

 

CMBS
70

 
(70
)
 

 

 

 

 

 

 

 

Loans
3,420

 
(191
)
 
(1,678
)
 
1,537

 

 

 
6,340

 
9,428

 
364

 

Net derivatives (2)
28,975

 
(14,760
)
 
(25
)
 
4,175

 
1,974

 

 
27,110

 
47,449

 
7,565

 

Long-term debt
283,139

 
1,163

 

 

 
(5,585
)
 
39,385

 
(81,540
)
 
236,562

 
(813
)
 
(350
)
(1)
Realized and unrealized gains/losses are primarily reported in Principal transactions revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes are included in our Consolidated Statement of Comprehensive Income, net of tax.
(2)
Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.
The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the six months ended May 31, 2020 (in thousands):
 
Six Months Ended May 31, 2020
 
 
 
Total gains/losses (realized and unrealized) (1)
 
 
 
 
 
 
 
 
 
Net transfers into/
 (out of) Level 3
 
 
 
For instruments still held at
May 31, 2020, changes in unrealized gains/(losses) included in:
 
Balance at November 30, 2019
 
 
Purchases
 
Sales
 
Settlements
 
Issuances
 
 
Balance at May 31, 2020
 
Earnings (1)
 
Other comprehensive income (1)
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
58,301

 
$
(12,860
)
 
$
2,989

 
$
(2,017
)
 
$

 
$

 
$
29,687

 
$
76,100

 
$
(12,787
)
 
$

Corporate debt securities
7,490

 
1,560

 
766

 
(479
)
 
(602
)
 

 
16,443

 
25,178

 
1,190

 

CDOs and CLOs
20,081

 
(14,223
)
 
9,426

 
(11,849
)
 
(3,193
)
 

 
22,897

 
23,139

 
(17,115
)
 

RMBS
17,740

 
(2,248
)
 
2,062

 

 
(10
)
 

 
4,795

 
22,339

 
(2,195
)
 

CMBS
6,110

 
(95
)
 

 

 
(1,660
)
 

 
106

 
4,461

 
(680
)
 

Other ABS
42,563

 
(2,848
)
 
33,917

 
(664
)
 
(17,361
)
 

 
30,455

 
86,062

 
(7,226
)
 

Loans and other receivables
64,240

 
(8,600
)
 
66,047

 
(76,227
)
 
(6,606
)
 

 
29,575

 
68,429

 
(11,689
)
 

Investments at fair value
75,738

 
(30,496
)
 
18,885

 
(168
)
 

 

 

 
63,959

 
(30,496
)
 

Securities purchased under agreements to resell
25,000

 

 

 

 
(25,000
)
 

 

 

 

 

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
4,487

 
$
216

 
$
(513
)
 
$

 
$

 
$

 
$

 
$
4,190

 
$
140

 
$

Corporate debt securities
340

 
(27
)
 
(150
)
 

 

 

 

 
163

 
5

 

CMBS
35

 

 
(35
)
 
140

 

 

 

 
140

 

 

Loans
9,463

 
1,072

 
(12,958
)
 
3,290

 

 

 
9,807

 
10,674

 
(1,075
)
 

Net derivatives (2)
77,168

 
(44,729
)
 
(11,088
)
 
38,823

 
(1,010
)
 

 
(14,033
)
 
45,131

 
32,211

 

Long-term debt
480,069

 
(101,267
)
 

 

 

 
175,498

 
(57,260
)
 
497,040

 
(4,802
)
 
106,069

(1)
Realized and unrealized gains/losses are primarily reported in Principal transactions revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes are included in our Consolidated Statements of Comprehensive Income, net of tax.
(2)
Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.
The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the six months ended May 31, 2019 (in thousands):
 
Six Months Ended May 31, 2019
 
 
 
Balance at November 30, 2018
 
Total gains/losses (realized and unrealized) (1)
 
Purchases
 
Sales
 
Settlements
 
Issuances
 
Net transfers into/
(out of) Level 3
 
Balance at May 31, 2019
 
For instruments still held at
May 31, 2019, changes in unrealized gains/(losses) included in:
 
Earnings (1)
 
Other comprehensive income (1)
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
51,040

 
$
6,126

 
$
785

 
$
(2,031
)
 
$
(720
)
 
$

 
$
4,107

 
$
59,307

 
$
7,972

 
$

Corporate debt securities
9,484

 
(389
)
 
1,545

 
(2,130
)
 
(1,177
)
 

 
96

 
7,429

 
(334
)
 

CDOs and CLOs
25,815

 
(2,790
)
 
4,782

 

 

 

 
(11,612
)
 
16,195

 
(2,554
)
 

RMBS
19,603

 
(316
)
 
39

 

 
(45
)
 

 
(2,015
)
 
17,266

 
(271
)
 

CMBS
10,886

 
(180
)
 
11

 
(331
)
 
(3,278
)
 

 
5,422

 
12,530

 
(1,183
)
 

Other ABS
53,175

 
(1,014
)
 
25,316

 
(13,247
)
 
(9,529
)
 

 
(11,516
)
 
43,185

 
(522
)
 

Loans and other receivables
46,985

 
2,434

 
77,004

 
(33,549
)
 
(3,378
)
 

 
8,988

 
98,484

 
844

 

Investments at fair value
113,831

 
(1,162
)
 
31,343

 

 

 

 
(40,179
)
 
103,833

 
(1,162
)
 

Securities purchased under agreements to resell

 

 

 

 

 
25,000

 

 
25,000

 

 

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$

 
$
(76
)
 
$
(1,546
)
 
$
1,843

 
$

 
$

 
$

 
$
221

 
$

 
$

Corporate debt securities
522

 
(382
)
 
(73
)
 
93

 
22

 

 
487

 
669

 
305

 

Loans
6,376

 
(401
)
 
(3,946
)
 
7,963

 

 

 
(564
)
 
9,428

 
579

 

Net derivatives (2)
21,614

 
(29,079
)
 
(2,829
)
 
7,259

 
2,031

 

 
48,453

 
47,449

 
19,607

 

Long-term debt
200,745

 
(12,854
)
 

 

 
(11,250
)
 
101,872

 
(41,951
)
 
236,562

 
3,827

 
9,027

(1)
Realized and unrealized gains/losses are primarily reported in Principal transactions revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes are included in our Consolidated Statements of Comprehensive Income, net of tax.
(2)
Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.
Quantitative Information about Significant Unobservable Inputs Used in Level 3 Fair Value Measurements
The tables below present information on the valuation techniques, significant unobservable inputs and their ranges for our financial assets and liabilities, subject to threshold levels related to the market value of the positions held, measured at fair value on a recurring basis with a significant Level 3 balance. The range of unobservable inputs could differ significantly across different firms given the range of products across different firms in the financial services sector. The inputs are not representative of the inputs that could have been used in the valuation of any one financial instrument (i.e., the input used for valuing one financial instrument within a particular class of financial instruments may not be appropriate for valuing other financial instruments within that given class). Additionally, the ranges of inputs presented below should not be construed to represent uncertainty regarding the fair values of our financial instruments; rather, the range of inputs is reflective of the differences in the underlying characteristics of the financial instruments in each category.
For certain categories, we have provided a weighted average of the inputs allocated based on the fair values of the financial instruments comprising the category. We do not believe that the range or weighted average of the inputs is indicative of the reasonableness of uncertainty of our Level 3 fair values. The range and weighted average are driven by the individual financial instruments within each category and their relative distribution in the population. The disclosed inputs when compared with the inputs as disclosed in other periods should not be expected to necessarily be indicative of changes in our estimates of unobservable inputs for a particular financial instrument as the population of financial instruments comprising the category will vary from period to period based on purchases and sales of financial instruments during the period as well as transfers into and out of Level 3 each period.
May 31, 2020
Financial Instruments Owned:
 
Fair Value
(in thousands)
 
Valuation Technique
 
Significant Unobservable Input(s)
 
Input / Range
 
Weighted
Average
Corporate equity securities
 
$
75,712

 
 
 
 
 
 
 
 
 
 
Non-exchange traded securities
 
Market approach
 
Price
 
$1
-
$213
 
$94
 
 
 
 
 
 
Underlying stock price
 
$3
 
 
 
 
 
 
 
EBITDA multiple
 
$3
-
$8
 
$4
Corporate debt securities
 
$
25,178

 
Market approach
 
Price
 
$69
 
 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
22%
 
CDOs and CLOs
 
$
23,139

 
Discounted cash flows
 
Constant prepayment rate
 
10
%
-
20%
 
16%
 
 
 
 
 
 
Constant default rate
 
2%
 
 
 
 
 
 
 
Loss severity
 
25
%
-
30%
 
28%
 
 
 
 
 
 
Discount rate/yield
 
14
%
-
32%
 
22%
RMBS
 
$
22,339

 
Discounted cash flows
 
Cumulative loss rate
 
3
%
-
33%
 
11
 
 
 
 
 
 
Duration (years)
 
2.0

-
6.1
 
5.6
 
 
 
 
 
 
Discount rate/yield
 
4
%
-
15%
 
5%
CMBS
 
$
4,461

 
Scenario analysis
 
Estimated recovery percentage
 
44%
 
Other ABS
 
$
86,062

 
Discounted cash flows
 
Cumulative loss rate
 
7
%
-
31%
 
14%
 
 
 
 
 
 
Duration (years)
 
0.4

-
2.8
 
1.4
 
 
 
 
 
 
Discount rate/yield
 
5
%
-
15%
 
9%
 
 
 
 
Market approach
 
Price
 
$100
 
Loans and other receivables
 
$
67,207

 
Market approach
 
Price
 
$1
-
$100
 
$81
 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
1
%
-
100%
 
61%
Derivatives
 
$
41,769

 
 
 
 
 
 
 
 
 
 
Equity options
 
 
 
Volatility benchmarking
 
Volatility
 
49%
 
Interest rate swaps
 
 
 
Market approach
 
Basis points upfront
 
1

-
16
 
8
Investments at fair value
 
$
63,959

 
 
 
 
 
 
 
 
 
 
Private equity securities
 
 
 
Market approach
 
Price
 
$6
-
$169
 
$49
 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
86%
 
Financial Instruments Sold, Not Yet Purchased:
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
 
$
4,190

 
Market approach
 
Transaction level
 
$1
 
Corporate debt securities
 
$
163

 
Scenario analysis
 
Estimated recovery percentage
 
22%
 
Loans
 
$
10,674

 
Market approach
 
Price
 
$1
-
$50
 
$33
 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
1%
 
Derivatives
 
$
83,576

 
 
 
 
 
 
 
 
 
 
Equity options
 
 
 
Volatility benchmarking
 
Volatility
 
33
%
-
62%
 
47%
Interest rate swaps
 
 
 
Market approach
 
Basis points upfront
 
0

-
16
 
7
Unfunded commitments
 
 
 
 
 
Price
 
$90
 
Long-term debt
 
 
 
 
 
 
 
 
 
 
 
 
Structured notes
 
$
497,040

 
Market approach
 
Price
 
$78
-
$94
 
$84
 
 
 
 
 
 
Price
 
€63
-
€109
 
€85
November 30, 2019
Financial Instruments Owned
 
Fair Value
(in thousands)
 
Valuation Technique
 
Significant Unobservable Input(s)
 
Input / Range
 
Weighted
Average
Corporate equity securities
 
$29,017
 
 
 
 
 
 
 
 
 
 
Non-exchange-traded securities
 
 
 
Market approach
 
Price
 
$1
-
$140
 
$55
 
 
 
 
 
 
Underlying stock price
 
$3
-
$5
 
$4
Corporate debt securities
 
$7,490
 
Scenario analysis
 
Estimated recovery percentage
 
23
%
-
85%
 
46%
 
 
 
 
 
 
Volatility
 
44%
 
 
 
 
 
 
 
Credit spread
 
750
 
 
 
 
 
 
 
Underlying stock price
 
£0.4
 
CDOs and CLOs
 
$20,081
 
Discounted cash flows
 
Constant prepayment rate
 
20%
 
 
 
 
 
 
 
Constant default rate
 
1
%
-
2%
 
2%
 
 
 
 
 
 
Loss severity
 
25
%
-
37%
 
29%
 
 
 
 
 
 
Discount rate/yield
 
12
%
-
21%
 
15%
RMBS
 
$17,740
 
Discounted cash flows
 
Cumulative loss rate
 
2%
 
 
 
 
 
 
 
Duration (years)
 
6.3
 
 
 
 
 
 
 
Discount rate/yield
 
3%
 
CMBS
 
$6,110
 
Discounted cash flows
 
Cumulative loss rate
 
7.3%
 
 
 
 
 
 
 
Duration (years)
 
0.2
 
 
 
 
 
 
 
Discount rate/yield
 
85%
 
 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
44%
 
Other ABS
 
$42,563
 
Discounted cash flows
 
Cumulative loss rate
 
7
%
-
31%
 
16%
 
 
 
 
 
 
Duration (years)
 
0.5

-
3.0
 
1.5
 
 
 
 
 
 
Discount rate/yield
 
7
%
-
15%
 
11%
Loans and other receivables
 
$62,734
 
Market approach
 
Price
 
$36
-
$100
 
$90
 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
87
%
-
104%
 
99%
Derivatives
 
$13,826
 
 
 
 
 
 
 
 
 
 
Interest rate swaps
 
 
 
Market approach
 
Basis points upfront
 
0

-
16
 
6
Unfunded commitments
 
 
 
 
 
Price
 
$88
 
Equity options
 
 
 
Volatility benchmarking
 
Volatility
 
45%
 
Investments at fair value
 
$75,736
 
 
 
 
 
 
 
 
 
 
Private equity securities
 
 
 
Market approach
 
Price
 
$8
-
$250
 
$125
Securities purchased under agreements to resell
 
$25,000
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Market approach
 
Spread to 6 month LIBOR
 
500
 
 
 
 
 
 
 
Duration (years)
 
1.5
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial Instruments Sold, Not Yet Purchased:
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
 
$4,487
 
Market approach
 
Transaction level
 
$1
 
Loans
 
$9,463
 
Market approach
 
Price
 
$50
-
$100
 
$88
 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
1%
 
Derivatives
 
$92,057
 
 
 
 
 
 
 
 
 
 
Equity options
 
 
 
Volatility benchmarking
 
Volatility
 
21
%
-
61%
 
43%
Interest rate swaps
 
 
 
Market approach
 
Basis points upfront
 
0

-
22
 
13
Cross currency swaps
 
 
 
 
 
Basis points upfront
 
2
 
Unfunded commitments
 
 
 
 
 
Price
 
$88
 
Long-term debt
 
 
 
 
 
 
 
 
 
 
 
 
Structured notes
 
$480,069
 
Market approach
 
Price
 
$84
-
$108
 
$96
 
 
 
 
 
 
Price
 
€74
-
€103
 
€91

Summary of Gains (Losses) Due to Changes in Instrument Specific Credit Risk and Summary of Contractual Principal Exceeds Fair Value for Loans and Other Receivables
The following is a summary of gains (losses) due to changes in instrument specific credit risk on loans, other receivables and debt instruments and gains (losses) due to other changes in fair value on Long-term debt and Short-term borrowings measured at fair value under the fair value option (in thousands):
 
Three Months Ended 
 May 31,
 
Six Months Ended 
 May 31,
 
2020
 
2019
 
2020
 
2019
Financial instruments owned:
 
 
 
 
 
 
 
Loans and other receivables
$
(13,926
)
 
$
(2,352
)
 
$
(10,830
)
 
$
(3,072
)
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
Loans
$
127

 
$

 
$
127

 
$

Loan commitments
1,750

 
(757
)
 
1,089

 
(678
)
Long-term debt:
 
 
 
 
 
 
 
Changes in instrument specific credit risk (1)
$
197,737

 
$
4,009

 
$
227,169

 
$
27,492

Other changes in fair value (2)
(30,982
)
 
(36,665
)
 
(68,624
)
 
(47,308
)
Short-term borrowings:
 
 
 
 
 
 
 
Changes in instrument specific credit risk (1)
$
35

 
$

 
$
91

 
$

Other changes in fair value (2)
(644
)
 

 
(881
)
 

(1)
Changes in instrument specific credit risk related to structured notes are included in our Consolidated Statements of Comprehensive Income, net of tax.
(2)
Other changes in fair value are included in Principal transactions revenues in our Consolidated Statements of Earnings.
The following is a summary of the amount by which contractual principal exceeds fair value for loans and other receivables, long-term debt and short-term borrowings measured at fair value under the fair value option (in thousands):
 
May 31, 2020
 
November 30, 2019
Financial instruments owned:
 
 
 
Loans and other receivables (1)
$
1,881,470

 
$
1,546,516

Loans and other receivables on nonaccrual status and/or 90 days or greater past due (1) (2)
331,340

 
197,215

Long-term debt and short-term borrowings
241,295

 
74,408

(1)
Interest income is recognized separately from other changes in fair value and is included in Interest revenues in our Consolidated Statements of Earnings.
(2)
Amounts include loans and other receivables 90 days or greater past due by which contractual principal exceeds fair value of $27.2 million and $22.2 million at May 31, 2020 and November 30, 2019, respectively.